European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy

On 21 November 2016, the European Commission issued a marketing authorisation valid throughout the European Union for ixazomib in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. Ixazomib was evalu...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:ESMO Open
Hoofdauteurs: Tzogani, Kyriaki, Florez, Beatriz, Markey, Greg, Caleno, Mariapaola, Olimpieri, Odoardo Maria, Melchiorri, Daniela, Hovgaard, Doris Johanna, Sarac, Sinan Bardakci, Penttilä, Karri, Lapveteläinen, Tuomo, Salmonson, Tomas, Bergh, Jonas, Gisselbrecht, Christian, Pignatti, Francesco
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: BMJ Publishing Group 2019
Onderwerpen:
Review
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6735670/
https://ncbi.nlm.nih.gov/pubmed/31555488
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2019-000570
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items